Original Research

An investigation of the views and practices of Australian community pharmacists on pain and fever management and clinical guidelines

John MISHRIKY1, Ieva STUPANS1, Vincent CHAN1

Received (first version): 20-Dec-2018 Accepted: 9-Jun-2019 Published online: 11-Jun-2019

Abstract

Background: Fever and pain are common conditions in the Australian healthcare setting. Whilst clinical guidelines provide important therapeutic recommendations, evidence suggests they are not always followed. Given that community pharmacy is one of the most frequently accessed primary healthcare services, it is important to understand the views and practices of community pharmacists in pain and fever.

Objectives: To investigate the views and practices of Australian community pharmacists in pain and fever management, and their views on relevant clinical guidelines.

Methods: A cross-sectional study of community pharmacists in Australia was conducted using a customised, anonymous, self-administered, online questionnaire between March and May 2018. To capture a broad range of demographics, pharmacists were recruited via local industry contacts and the Pharmaceutical Society newsletter, with further recruitment through snowball sampling. The main outcomes measured were pharmacists’ views, practices and treatment recommendation of choice in pain and fever management, as well as views on clinical guidelines and training.

Results: A total of 113 pharmacists completed the survey. In general, paracetamol (72%) was preferred as a recommendation over ibuprofen, and was the drug of choice for most mild to moderate pain and fever scenarios. Majority of pharmacists reported good knowledge of pain and fever management, however, only approximately half reported recent pain management training. Greater than 87% of pharmacists believe that clinical guidelines are useful in fever management, and 79% of pharmacists believe that following clinical guidelines is important in pain management.

Conclusions: While most pharmacists recognise the importance of guidelines and demonstrated good pain and fever management, results suggest opportunities to promote additional education, upskilling, and research in this space to further optimise pain and fever management in the community.

Keywords

Pain; Fever; Pain Management; Acetaminophen; Ibuprofen; Pharmacies; Pharmacists; Choice Behavior; Professional Practice; Surveys and Questionnaires; Australia

INTRODUCTION

Australian community pharmacies are considered to be important sources of a wide range of healthcare services, and are regularly the first point of contact for most patients due to convenience, accessibility and availability of a plethora of medications at reasonable costs.1,3

Primary healthcare professionals require reliable and up-to-date evidence and clinical information (for example clinical guidelines) to assist in making the most appropriate and safest therapeutic decision for patients.4,5 The importance of healthcare professionals appreciating and adhering to clinical guidelines is amplified particularly when patients present with symptoms that potentially warrant thorough medical analysis prior to initiating pharmacotherapy. Pharmacists should familiarise themselves with the medical recommendations adopted in Australian healthcare practices, given that community pharmacies are one of the most frequently and easily accessed primary healthcare services.

In Australia, it is well documented that pain and fever symptoms are common complaints expressed by patients of all age groups.6-8 Failure to adequately manage pain and fever symptoms can have a significant impact on patient outcome and exacerbation of additional health consequences. Community pharmacists hold an advisory position and have an opportunity to effectively engage with patients and assess whether pharmacological management of pain and fever symptoms are appropriate and are attuned to the current clinical recommendations. For example, The National Institute for Health and Care Excellence (NICE) provides clinical guidelines to Australian healthcare practitioners and pharmacists on the diagnosis, assessment and treatment of feverish illness, for example using paracetamol or the Non-Steroidal Anti-Inflammatory drug (NSAID) ibuprofen; while the Australian Therapeutic Guidelines (TG) provides clinical guidelines on the general assessment and management of pain, including the ‘Stepwise’ approach adopted for pharmacological management of acute and chronic pain in Australia, such as using paracetamol, NSAIDs and/or opioids, depending on the nature of the pain.9,10
Interestingly, despite the importance of clinical guidelines to clinical practice, studies investigating whether guidelines are generally adhered to, or evidence supporting that clinical guidelines are being followed by healthcare professionals (particularly pharmacists) are quite variable. For example, despite significant efforts to promote and support guideline use, evidence indicates that adherence to guidelines by healthcare professionals is often suboptimal.\textsuperscript{11,12}

Thus, given the currently limited published literature in this context, it is important to understand and explore the views and perceptions of community pharmacist on the usefulness of clinical guidelines on pain and fever management, as well as as assessing their usual practices, particularly investigating whether Australian pharmacists appreciate clinical guidelines, and apply them in this context.

The aim of this study was to investigate the current views and self-reported practices of Australian community pharmacists in pain and fever management, how they compared to current clinical guidelines and recommendations, and to identify the potential gaps and opportunities in this space.

METHODS

Ethics approval

This study was approved by the Human Research Ethics Committee of the study institution (Approval number: SEHAPP 99-17).

Study participants

This study was designed as a cross-sectional study to capture the current views and self-reported practices of Australian practicing community pharmacists in commonly encountered pain and fever management, as well as their views on clinical guidelines. Data collection was conducted over an approximately eight-week period (March-May 2018). Participation involved completing an anonymous online survey that took approximately 10 minutes. This survey was open to all community pharmacists across Australia, although it is estimated that survey participants would be predominately pharmacists in Victoria, due to the recruitment. Implied consent was sought by completion of the survey. The investigators were responsible for the initial recruitment of pharmacists via local industry contacts and the Pharmaceutical Society of Australia newsletter, with further recruitment through snowball sampling.

Questionnaire

An anonymous, self-administered questionnaire was developed to collect a broad range of data from Australian community pharmacists. Qualtrics software was used to develop and deliver the online questionnaire.

Questions were developed under four sections. To ensure that a broad range of pharmacist responses were captured, demographic data such as age, gender, employment status, area of primary employment, tertiary qualifications and approximate years of experience as an Australian registered pharmacist were obtained.

The main body of the questionnaire consisted of questions relating to daily pharmacy practice observations, which included questions on the most common types of pain, and the frequency of over-the-counter (OTC) analgesic requests. In the next section, pharmacists were presented with a series of hypothetical case scenarios of patients presenting to the pharmacy with symptoms of either fever or pain with different severities. The case scenarios are patient-based presentations typically seen in an Australian community pharmacy setting. Examples of scenarios include: general mild to severe musculoskeletal pain, headaches, migraines, osteoarthritis and fever; as well as preference for treatment options relating to adults and paediatric assessments of fever. Pharmacists were provided with a number of different available treatment (no brand names were used) and referral options, and were asked to select their preferred treatment strategy in each case (given that there are no contraindications in the case scenarios).

The final section of the questionnaire consisted of a series of categorical questions (5-point Likert scale ranging from Strongly disagree to Strongly agree) investigating the pharmacist’s views and opinions on their knowledge, training, clinical guidelines and clinical experience in the context of pain and fever management.

The questionnaire underwent a series of pilot tests with a small group of pharmacists and pharmacy academics before final release. The survey was preliminarily pre-tested for ease of use and to identify any technical or interpretative issues, and a second round of pilot tests were conducted before the questionnaire was made available to Australian community pharmacists.

Data analysis

Statistical tests and descriptive statistics were conducted (using SPSS version 18) to assess responses to the questionnaire. A Chi-square goodness-of-fit analysis was also performed to specifically compare the demographic parameters of age and gender distributions of this study’s surveyed population with Pharmacy Board registrant data to assess sampling and external validity.

RESULTS

Of the total of 149 pharmacists who attempted the survey, 36 incomplete submissions were excluded, with 113 completed responses used for this study. Table 1 describes the participant demographics. Registrant data was retrieved from the Pharmacy Board of Australia for the period 1 January-31 March 2018.\textsuperscript{31} The eligible responses (n=113) were multiplied by the proportions of each category in the registrant data, to determine the expected frequency of responses to the survey. The expected frequency was then compared to the actual/observed frequency of responses to the survey to determine any distribution differences between the survey data of pharmacists in this study, and the registrant data of pharmacists.

The chi-square goodness-of-fit test showed a statistically significant difference in the age distribution between the survey and registrant data (computed chi-square value (chi-
of the majority of the pharmacists reported having recent pain management training. Majority of the pharmacists agreed that guidelines are both useful and important, however, many also believed that "Clinical experience" is just as important as the recent pain management training. Only approximately half of the pharmacists report having recent pain management training. Majority of the pharmacists agreed that guidelines are both useful and important, however, many also believed that "Clinical experience" is just as important as the recent pain management training. Only approximately half of the pharmacists report having recent pain management training. Majority of the pharmacists agreed that guidelines are both useful and important, however, many also believed that "Clinical experience" is just as important as the recent pain management training. Only approximately half of the pharmacists report having recent pain management training. Majority of the pharmacists agreed that guidelines are both useful and important, however, many also believed that "Clinical experience" is just as important as the recent pain management training. Only approximately half of the pharmacists report having recent pain management training. Majority of the pharmacists agreed that guidelines are both useful and important, however, many also believed that "Clinical experience" is just as important as the recent pain management training.

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).

Paracetamol was the medicine of choice for mild headaches; however, the preference for 'ibuprofen' or combination 'Paracetamol+ibuprofen' increases as severity increase (Table 3). Aspirin was the medicine of choice in adult mild-moderate migraines; with 'Referral' being the option of choice for severe migraine (Table 3). Paracetamol was the medicine of choice for mild-moderate osteoarthritis (Table 3). Ibuprofen was the medicine of choice for adult mild musculoskeletal pain; 'Diclofenac' or 'Referral' were the options of choice as severity increases (Table 3).
Table 3. Treatment options selected by pharmacists for adult presentations of musculoskeletal, tension headache, migraine headache and osteoarthritis pain scenarios

|               | Paracetamol | Ibuprofen | Diclofenac | Aspirin | Paracetamol/ Ibuprofen | Ibuprofen Gel | Diclofenac Gel | Referral | Other/s |
|---------------|-------------|-----------|------------|---------|------------------------|---------------|---------------|----------|---------|
| **Musculoskeletal Pain** |             |           |            |         |                        |               |               |          |         |
| Mild          | 15.0        | 40.7      | 11.5       | 0       | 10.6                   | 2.7           | 12.4          | 0.9      | 6.2     |
| Moderate      | 4.4         | 23.0      | 36.3       | 0       | 26.4                   | 1.8           | 1.8           | 0.9      | 5.4     |
| Severe        | 0           | 1.8       | 21.2       | 0       | 19.5                   | 0             | 0.9           | 41.6     | 15.0    |
| **Tension Headache Pain** |             |           |            |         |                        |               |               |          |         |
| Mild          | 39.8        | 27.4      | 0          | 7.0     | 14.2                   | 0             | 0             | 0.9      | 10.7    |
| Moderate      | 14.2        | 16.9      | 0.9        | 10.6    | 38.9                   | 0             | 0             | 3.5      | 15.0    |
| Severe        | 1.8         | 3.5       | 1.8        | 6.2     | 19.5                   | 0             | 0             | 52.2     | 15.0    |
| **Migraine Headache Pain** |             |           |            |         |                        |               |               |          |         |
| Mild          | 14.2        | 21.2      | 0          | 35.4    | 18.6                   | 0             | 0             | 2.7      | 7.9     |
| Moderate      | 0.9         | 11.5      | 1.8        | 31.9    | 31.0                   | 0             | 0             | 3.5      | 19.4    |
| Severe        | 0           | 1.8       | 1.8        | 13.3    | 6.2                    | 0             | 0             | 52.2     | 24.7    |
| **Osteoarthritis Pain** |             |           |            |         |                        |               |               |          |         |
| Mild          | 69.0        | 3.5       | 2.7        | 0       | 7.1                    | 0             | 0             | 10.6     | 6.2     |
| Moderate      | 30.1        | 5.3       | 11.5       | 0       | 31.9                   | 0             | 4.4           | 4.4      | 12.4    |
| Severe        | 2.7         | 0         | 7.1        | 0       | 14.2                   | 0             | 0             | 65.5     | 10.5    |

Patients frequently visit the pharmacists for pain treatment and patients frequently use OTCs to self-manage their pain.4,15

Although studies and meta-analyses comparing the effectiveness, safety and tolerability profiles of paracetamol and ibuprofen have led to variable conclusions, many studies identified that ibuprofen is as safe and effective as paracetamol in many basic analgesic and fever scenarios, in both adult and paediatric populations.16-20 Despite this, globally paracetamol is still perceived as having a better safety and overall better tolerability profile than ibuprofen.17 It was also suggested several reasons why this perception exists, including lack of distinction between the different Non-steroidal anti-inflammatory drugs (NSAIDs) resulting in a “class effect bias”; ingrained negative perceptions of NSAIDs, as well as lack of overall understanding with regards to ibuprofen safety and tolerability, and the lack of confidence to put this knowledge into practice.17 However, it is important to also recognise the risk of hepatic toxicity associated with paracetamol, particularly in high doses.

Interestingly, despite the popularity of OTC paracetamol and ibuprofen use, studies examining perceptions and practices of healthcare professionals and their preference for recommending paracetamol or ibuprofen are quite limited. One study examining non-prescription medicines for pain and fever identified that paracetamol was clearly the recommendation of choice by pharmacy staff, compared to NSAIDs.21 Furthermore, that study also reported a small proportion of staff recommending NSAIDs when paracetamol was requested by the patient.22 This is supported in a large national cross-sectional study of NSAID use by GPs, paediatricians and pharmacists where NSAIDs were only recommended in a minority of cases.22 Furthermore, it was identified that NSAIDs use was generally associated with older children, higher temperatures, pain due to otitis and in the absence of a rash or gastroenteritis.22 In a study looking at analgesics recommended by dentists and pharmacists, it was reported that ibuprofen was the OTC analgesic preferred and recommended by majority of both dentists and pharmacists for toothache relief in adults, with paracetamol as the second-choice agent.23

Choice of NSAID

Aspirin, ibuprofen, diclofenac and naproxen are the four OTC non-selective NSAIDs available in different formulations in Australia. The current Australian Therapeutic Guidelines suggests paracetamol as the second-line treatment option for mild acute pain when non-pharmacological treatment strategies are inadequate.23 As the severity of pain increases, the use of a NSAID may be warranted and the choice of which NSAID is at the healthcare professional’s discretion. In moderate acute pain, clinical guidelines list ibuprofen as the drug of choice because of the widespread experience with its use.10 In migraine pain presentations, guidelines suggest the use of high dose (900-1000 mg) soluble aspirin as a suitable NSAID. Results of this study suggest that Australian

Table 4. Community pharmacists’ views and perceptions on pain management

|                                      | Strongly Disagree | Disagree | Neither Agree nor Disagree | Agree | Strongly Agree |
|--------------------------------------|-------------------|----------|---------------------------|-------|----------------|
| **a) My knowledge of PAIN management is good** | 1.8               | 4.4      | 19.5                      | 63.7  | 10.6           |
| **b) I could benefit from some additional training when it comes to PAIN management** | 1.8               | 0        | 8.8                       | 61.1  | 28.3           |
| **c) Clinical guidelines are USEFUL when it comes to PAIN management** | 0.9               | 3.5      | 11.5                      | 61.9  | 22.1           |
| **d) Following clinical guidelines is IMPORTANT when it comes to PAIN management** | 0.9               | 0.9      | 19.5                      | 61.1  | 17.7           |
| **e) Clinical experience is more useful than following clinical guidelines when it comes to PAIN management** | 0.9               | 27.4     | 35.4                      | 25.7  | 10.6           |
| **f) Me general preference is to recommend paracetamol over ibuprofen** | 0.9               | 8.0      | 19.5                      | 51.3  | 20.4           |
pharmacists are aware of the fact that soluble aspirin is the drug of choice in migraine pain symptoms, since it was the most selected treatment option in the hypothetical migraine pain cases. The Australian Medicines Handbook (AMH) advises medical practitioners and pharmacists that approximately 60% of patients will respond to any NSAIDs, and those who do not respond to one may respond to another.  

Diclofenac has the least potential of causing gastrointestinal side effects but has the highest risk of causing adverse cardiovascular effects.  

Results from this study identified that diclofenac was the NSAID of choice as the severity of musculoskeletal pain increases in the hypothetical case scenarios. Motives behind the popularity of diclofenac in these instances remain unclear, although its availability in a specialised oral formulation with a more rapid absorption rate, and the fact that diclofenac has the shortest half-life, could be contributing reasons.  

The results in this particular section are not attuned to the recommendations of the clinical guidelines as diclofenac is listed as a second-line therapy (after ibuprofen) for moderate symptoms of pain. However, it is important to note that clinical guidelines do not provide conclusive information on the comparative efficacy of the varying NSAID options, and hence guidelines advise health professionals to select a suitable NSAID based on patient comorbidities.  

Although studies comparing the effectiveness and safety profiles of diclofenac to other NSAIDs have led to variable conclusions, studies have identified that diclofenac is no more effective than other NSAIDs such as ibuprofen. The difference between the results in the moderate pain scenarios and clinical guideline recommendations for moderate pain management highlights that there may be additional factors influencing a pharmacist’s decision when recommending a suitable NSAID option.

Clinical guidelines vs clinical experience

Both clinical guidelines and clinical experience are critical to the application of evidence-based practice and are essential to patient care. The growth of research evidence impacts its translation into clinical guidelines, which impacts clinical practice. Many chronic conditions such as pain is currently under-diagnosed and under-treated and is likely to worsen unless there is a wider adoption of best pain management practice. Primary care management should be holistic and evidence-based, incorporating both pharmacological and non-pharmacological approaches, including complementary therapies and comprehensive management programs.

Although there is evidence to support the role of the community pharmacist in chronic disease management, it has been identified that a pharmacist’s skills, for example pain management, is often not fully utilised. Evidence suggests that chronic non-cancer pain (CNCP) management in primary care is suboptimal and barriers to optimal management are numerous. These includes clinician’s knowledge and experience, particularly their perceptions on following and trusting in clinical guidelines. It is recognised that whilst guideline recommendations should be acknowledged, their implementation in practice may differ due to the complexity of perceptions and expectations, and due to the importance of focussing on the patient holistically.

Interestingly, despite the importance of clinical guidelines to clinical practice, evidence supporting that clinical guidelines are being followed by healthcare professionals (particularly pharmacists) are more limited and variable. Despite significant efforts to promote and support guideline use, evidence indicates that adherence to guidelines for both pain and fever is often suboptimal despite its availability. It has been suggested that some pharmacists may even lack adequate knowledge of evidence-based practice for OTC medicines and make recommendations that lack evidence. Further, it has also been identified that barriers to adherence vary not only across guidelines but also across recommendations within guidelines.  

Understanding and identifying barriers to evidence-based guidelines’ uptake is critical to closing the “evidence-practice” gap. It has been suggested that the use of guidelines is influenced by the believability of the underlying evidence, the health practitioner’s consultation style, and uncertainties surrounding diagnosis and treatment. Other barriers include perceptions of the condition’s seriousness, clinicians’ preparedness, clinicians’ personal beliefs, and dissonant patient expectations. A systematic review also identified that many clinicians viewed guidelines were categorical, prescriptive, and constrained professional practice. Other studies among GPs have also demonstrated that barriers across guideline adherence are patient related, suggesting that guidelines do not always adequately incorporate patient preferences, needs and abilities. Additionally, it was also noted that popular clinical practices superseded the guidelines, with adherence to following protocols decreasing with increasing physician experience. Interestingly, clinicians’ perceptions of guidelines often also demonstrates a lack of content knowledge, as well as a lack of appreciation of and trust in how guidelines are developed. This indicates that targeted education on these aspects could be important in this context.

Table 5. Community pharmacists’ views and perceptions on fever management

| Strongly Disagree | Disagree | Neither Agree nor Disagree | Agree | Strongly Agree |
|-------------------|---------|---------------------------|-------|---------------|
| a) My knowledge of FEVER management is good | 0.9 | 4.4 | 14.2 | 65.5 | 15.0 |
| b) Clinical guidelines are USEFUL when it comes to FEVER management | 0.9 | 0.9 | 10.6 | 76.1 | 11.5 |
| c) Following clinical guidelines is IMPORTANT when it comes to FEVER management | 0.9 | 0.9 | 16.8 | 65.5 | 15.9 |
| d) Clinical experience is more useful than following clinical guidelines when it comes to FEVER management | 3.5 | 23.0 | 42.5 | 26.5 | 4.4 |
Limitations and future directions

Although a broad range of demographics were captured, it is likely that the pharmacists in this study do not fully represent all pharmacists. A larger sample size will increase generalizability of the results. To assess this, demographics data was compared with the Pharmacy Board registrant data. Furthermore, potential selection bias may also exist that can also influence sample representativeness. Another limitation of this study was that it was only designed to assess self-reported practice; the use of the simulated patient technique may be a more appropriate way to assess actual practice. Indeed, the use of simulated patients to assess analgesic recommendations have previously been reported in other contexts.\(^\text{42,43}\) Additionally, as this was a self-reported survey, response bias is possible. To minimise this, pharmacists were not explicitly told that their views were being compared to guidelines and were simply asked to suggest their recommendation of choice for the scenarios. To extend this work, it would be useful to further identify specific areas where practices may not align with guidelines, as well as further understanding how best practice guidelines can be optimally utilised to guide practice and decision making, including key drivers and barriers for specific views and practices, with the ultimate goal of improving patient care and health outcomes.

CONCLUSIONS

Pain and fever symptoms are common presentations experienced by Australians and inadequate assessment and management can result in significant impacts on the health and wellbeing of patients. Majority of the pharmacists in this study report and demonstrate good knowledge of pain and fever management. Furthermore, this study also comprehensively reported the practices of Australian community pharmacists in various pain and fever scenarios, as well as their views on pain and fever management and clinical guidelines. Although healthcare professionals largely accept and adopt relevant evidence-based clinical guidelines, they may not always be strictly followed. Results from this study suggest a great potential to structure and develop further research studies in this space, as well as the importance to further facilitate training, education and resources for pharmacists that are consistent with the recommendations outlined by clinical guidelines and latest available evidence.

ACKNOWLEDGEMENTS

The authors would like to thank the pharmacists who participated in the survey for their valuable insights and comments. We would also like to acknowledge Reckitt Benckiser Australia for supporting this study, and CHE Proximity for assisting with the communications and facilitation of this study.

CONFLICT OF INTEREST

This study was supported in part by a research agreement with Reckitt Benckiser Australia. The authors’ work and results of this study were otherwise independent of the funders. The authors have no other affiliations with the funders.

FUNDING

This study was supported in part by a research agreement with Reckitt Benckiser Australia. The funding had no impact on the study and survey development, results, or the analyses of the results of this independent study. Reckitt Benckiser has a health portfolio in pain and fever management products, however there were no references to the company or specific brand products in the questionnaire.

References

1. Benrimoj SI, Frommer MS. Community pharmacy in Australia. Aust Health Rev. 2004;28(2):238-246.
2. Roberts AS, Benrimoj SIC, Chen TF, Williams KA, Hopp TR, Aslani P. Understanding practice change in community pharmacy: a qualitative study in Australia. Res Social Adm Pharm. 2005;11(4):546-564. https://doi.org/10.1016/j.sapharm.2005.09.003
3. Cannings J, Francis C, Jessop R. Consumer needs executive summary - 5th community pharmacy agreement. Australian Government Department of Health; 2015.
4. Amorin-Woods L, Beck R, Parkin-Smith G, Lougheed J, Brenmer A. Adherence to clinical practice guidelines among three professional contact professions: a best evidence synthesis of the literature for the management of acute and subacute low back pain. J Can Chiropr Assoc. 2014;58(3):220-237.
5. Corbett M, Foster N, Ong BN. GP attitudes and self-reported behaviour in primary care consultations for low back pain. Fam Pract. 2009;26(5):359-364. https://doi.org/10.1093/fampra/cmp042
6. El-Radhi AS, El-Radhi AS, Carroll J, Klein N. Clinical Manual of Fever in Children. El-Radhi ASe, Carroll Je, Klein Ne, editors. Berlin: Springer; 2009.
7. Strong J, Melzauck R, Van Griensven H, Strong J, Unruh AM. Pain : a textbook for health professionals. Second edition. ed. Edinburgh, New York: Churchill Livingstone/Elsevier; 2014.
8. Australian Bureau of Statistics. Characteristics of bodily pain in Australia. 4841.0- Facts at your fingertips. Available at: http://www.abs.gov.au/ausstats/abs@.nsf/Lookup/4841.0Chapter12011 (accessed Dec 20, 2018).
9. NICE. Fever in under 5s: assessment and initial management [Internet]. United Kingdom: National Institute for Health and Care Excellence. Available from: https://www.nice.org.uk/guidance/cg160 (accessed Dec 20, 2018).
10. Acute pain: a general approach, In: eTG complete. Melbourne: Therapeutic Guidelines Limited; 2018.
11. Lugtenberg M, Burgers JS, Beetsers CF, Han D, Westert GP. Perceived barriers to guideline adherence: a survey among general practitioners. BMC Fam Pract. 2011;12:98. https://doi.org/10.1186/1471-2296-12-98

www.pharmacypractice.org (eISSN: 1886-3655 ISSN: 1885-642X)
12. Slade SC, Kent P, Patel S, Bucknall T, Buchbinder R. Barriers to primary care clinician adherence to clinical guidelines for the management of low back pain. Clin J Pain. 2016;32(9):800-816. https://doi.org/10.1097/AJP.00000000000000324

13. Pharmacy Board of Australia: Statistics AHPR. Available at: http://www.pharmacyboard.gov.au/About/Statistics.aspx (accessed Dec 20, 2018).

14. Blyth FM, March LM, Brnabic AJM, Cousins MJ. Chronic pain and frequent use of health care. Pain. 2004;111(1-2):51-58. https://doi.org/10.1016/j.pain.2004.05.020

15. Brabers AEM, Van Dijk L, Bouvy ML, De Jong JD. Where to buy OTC medications? A cross-sectional survey investigating consumers' confidence in over-the-counter (OTC) skills and their attitudes towards the availability of OTC painkillers. BMJ Open. 2013;3(9):e003455. https://doi.org/10.1136/bmjopen-2013-003455

16. Crook J. Fever management: evaluating the use of ibuprofen and paracetamol. Paediatr Nurs. 2010;22(3):22-26. https://doi.org/10.7748/paed2010.04.22.3.22.e7638

17. Kanabar D. A clinical and safety review of paracetamol and ibuprofen in children. Inflammopharmacology. 2017;25(1):1-9. https://doi.org/10.1007/s10787-016-0302-2

18. McSwan J, Scarf A. Managing children's pain and fever with ibuprofen. Aust Pharm. 2017;36(6):28-31.

19. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44(3):489-506. https://doi.org/10.1345/aph.1M332

20. Wong T, Stang AS, Gans SL, Cheng SP, Kruger I, Yia GS, Nguyen NT, Kaushik M, White J, Milton S, Stang A. A comparison of paracetamol, ibuprofen, and diclofenac potassium for pain relief following dental extractions and deep cavity preparations. Cochrane Database Syst Rev. 2013;(10):CD009572. https://doi.org/10.1002/14651858.CD009572.pub2

21. Bardage C, Westerlund T, Barzi S, Bernstein C. Non-prescription medicines for pain and fever—A comparison of recommendations and counselling from staff in pharmacy and general sales stores. Health Policy. 2013;110(1):76-83. https://doi.org/10.1016/j.healthpol.2012.12.006

22. Bertille N, Pons G, Fournier-Charrière E, Khooshnoob B, Chaumeeau M. National cross-sectional study of nonsteroidal anti-inflammatory drugs use highlights differences between parents and professionals and prompts safety concerns. Acta Paediatr. 2016;105(11):e943-e948. https://doi.org/10.1111/apa.13566

23. Bhati M, Duxbury AJ, Maclarlane TV, Downer MC. Analgesics recommended by dentists and pharmacists, and used by the general public for pain relief. Int J Health Promot Educ. 2000;38(3):95-103. https://doi.org/10.1080/14635240.2000.10806157

24. Australian Medicines Handbook. Adelaide: Australian Medicines Handbook Pty; 2018.

25. Olsen AM, Fosbel EL, Lindhardsen J, Andersson C, Folke F, Nielsen MB, Keber L, Hansen PR, Torp-Pedersen C, Gislason GH. Cause-specific cardiovascular risk associated with nonsteroidal anti-inflammatory drugs among myocardial infarction patients—a nationwide study. PLoS One. 2013;8(1):e54309. https://doi.org/10.1371/journal.pone.0054309

26. Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015;55(6):778-783. https://doi.org/10.1111/1526-4610.12939

27. Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17(6):275-342. https://doi.org/10.1007/s10777-009-0016-x

28. Collins SL, Moore RA, McQuay HJ, Wilfen PJ. Oral ibuprofen and diclofenac in post-operative pain: a quantitative systematic review. Eur J Pain. 1998;2(4):285-291. https://doi.org/10.1016/S1090-8405(98)00027-1

29. Gazzal G, Al-Samadani KH. Comparison of paracetamol, ibuprofen, and diclofenac potassium for pain relief following dental extractions and deep cavity preparations. Saudi Med J. 2017 Mar;38(3):284-291. https://doi.org/10.1594/smj.2017.13.16023

30. Morán M. An observer-blind comparison of diclofenac potassium, piroxicam and placebo in the treatment of ankle sprains. Curr Med Res Opin. 1990;12(12):288-297. https://doi.org/10.1185/03007999009111657

31. Moore N. Diclofenac Potassium 12.5mg Tablets for Mild to Moderate Pain and Fever. Clin Drug Investig. 2007;27(3):163-195. https://doi.org/10.2165/00064401-200727030-00002

32. Pergolizzi J, Ahieck B, Aldington D, Alon E, Coluzzi F, Dahan A, Huygen F, Kooc-Stepska M, Mangas AC, Mavrocordatos P, Morion B, Müller-Schwefe G, Nicolaou A, Pérez Hernández C, Sicérie P, Schäfer M, Varrassi G. The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment. Curr Med Res Opin. 2013;29(9):1127-1135. https://doi.org/10.1185/03007995.2013.810615

33. Mills S, Torrance N, Smith BH. Identification and management of chronic pain in primary care: a review. Curr Psychiatry Rep. 2016;18(2):22. https://doi.org/10.1007/s11920-015-0659-9

34. George PP, Molina J, Cheah J, Chan SC, Lim BP. The evolving role of the community pharmacist in chronic disease management—a literature review. Ann Acad Med Singapore. 2010;39(11):861-867.

35. Kress H-G, Aldington D, Alon E, Coaccioli S, Collett B, Coluzzi F, Huygen F, Jaksch W, Kalso E, Kooc-Kępska M, Mangas AC, Ferri CM, Mavrocordatos P, Morion B, Müller-Schwefe G, Nicolaou A, Pérez Hernández CP, Sicérie P, Schäfer M, Varrassi G. A holistic approach to chronic pain management that involves all stakeholders: change is needed. Curr Med Res Opin. 2015;31(8):1743-1754. https://doi.org/10.1185/03007995.2015.1072086

36. Lalonde L, Choinière M, Martin E, Lévesque L, Hudon E, Bélanger D, Perreault S, Lacasse A, Laliberté MC. Priority interventions to improve the management of chronic non-cancer pain in primary care: a participatory research of the ACCORD program. J Pain Res. 2015;8:203-215. https://doi.org/10.2147/JPR.S76177

37. Williams CM, Maher CG, Hancock MJ, McAuley JH, McLachlan AJ, Britt H, Fathirdin S, Harrison C, Latimer J. Low back pain and best practice care: a survey of general practice physicians. Arch Intern Med. 2010;170(3):271-277. https://doi.org/10.1001/archinternmed.2009.507

38. Rafaeli G, Orenti A, Gambino M, Peves Rios W, Bosis S, Bianchini S, Tagliabue C, Esposito S. Fever and pain management in childhood: healthcare providers’ and parents’ adherence to current recommendations. Int J Environ Res Public Health. 2016;13(5):499. https://doi.org/10.3390/ijerph13050499
39. Hanna LA, Hughes CM. Pharmacists’ attitudes towards an evidence-based approach for over-the-counter medication. Int J Clin Pharm. 2012;34(1):63-71. https://doi.org/10.1007/s11096-011-9586-y

40. Egerton T, Diamond L, Buchbinder R, Bennell K, Slade S. A systematic review and evidence synthesis of qualitative studies to identify primary care clinicians' barriers and enablers to the management of osteoarthritis. Osteoarthritis Cartilage. 2017;25(5):625-638. https://doi.org/10.1016/j.joca.2016.12.002

41. Teng KA, Butler RS, Schramm S, Isaacson JH, Nielsen C, Paradis C. Physicians caring for physicians: the perspective of the primary care physician. South Med J. 2014;107(5):301-305. https://doi.org/10.1097/SMJ.000000000000095

42. Abdu-Agyue SN, Shehu A, Ahmad UI. Management of musculoskeletal pain in retail drug outlets within a Nigerian community: a descriptive study. Pharm Pract (Granada). 2017;15(1):873. https://doi.org/10.18549/PharmPract.2017.01.873

43. Santos AP, Mesquita AR, Oliveira KS, Lyra DP Jr. Assessment of community pharmacists’ counselling skills on headache management by using the simulated patient approach: a pilot study. Pharm Pract (Granada). 2013;11(1):3-7.